Natera, Inc. announced the results from the DNAFirst trial, showing that non-invasive prenatal screening tests (NIPT) can be effectively and appropriately offered as a primary screen for all pregnant women, regardless of risk due to maternal age or other factors. This is the first report of a routine clinical use of cfDNA-based prenatal screening for common aneuploidies in a general U.S. population, offered through primary obstetric care providers. The results of this study were published on January 12, 2017 online in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics. The DNAFirst study, led by Glenn E. Palomaki, Ph.D., of Brown University and Women and Infant's Hospital in Rhode Island, involved 2,681 women who were screened with Panorama® through 72 healthcare providers in Rhode Island. Pre-test counseling was provided solely by the women's primary obstetrical care provider, including women's physicians, nurse midwives and nurse/educators. The median patient age was 31 years, with approximately 79% of participating women less than 35 years of age. In the study, Panorama's performance in this general risk population was consistent with previously published clinical validation and experience data with excellent sensitivity (12/12) with no false negatives in the cohort, 75% positive predictive value (PPV) across all conditions and 0.15% combined false positive rate (FPR). Screening reports were issued to 99.85% of women in the study who were tested, after retesting as needed by either NIPT or serum screening. In a survey conducted following the study, women reported sufficient time to talk with their provider (95%), having their questions answered (96%) and felt the optional nature of screening was conveyed (99%). The majority of women correctly recalled that the NIPT was not diagnostic and evaluated risk for a limited number of conditions. Approximately 93% of women rated their decision to consent to the screening as 'good' or 'great' and nearly all would recommend NIPT to a friend (98%) or undergo the test in their next pregnancy (95%). Providers were given a short (10-20 minute) in-service education at a convenient location, questions were answered and patient education /test requisitions provided. Following completion of the study, 83% of providers surveyed believed they and their staff were adequately prepared to implement NIPT in their practice, without the need for additional, more extensive education.